<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576457</url>
  </required_header>
  <id_info>
    <org_study_id>AI471-049</org_study_id>
    <nct_id>NCT02576457</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis</brief_title>
  <official_title>A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects With Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether BMS-936559 is safe and has the desired
      pharmacologic activity in patients who have severe sepsis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Objectives Have Changed
  </why_stopped>
  <start_date type="Actual">December 2, 2015</start_date>
  <completion_date type="Actual">March 15, 2017</completion_date>
  <primary_completion_date type="Actual">March 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Safety of BMS-936559 in subjects with severe sepsis - measured by the incidence rates of death, AEs, SAEs, AEs leading to discontinuation, AEs of special interest and laboratory abnormalities</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>Safety will be measured by the incidence rates of death, Adverse event (AEs), Serious adverse event (SAEs), AEs leading to discontinuation, AEs of special interest (identified from PD-L1 oncology trial), and laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Tolerability of BMS-936559 in subjects with severe sepsis</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>Tolerability will be measured by the incidence rates of death, AEs, SAEs, AEs leading to discontinuation, AEs of special interest (identified from PD-L1 oncology trial), and laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: All-cause mortality within 90 days of study drug administration</measure>
    <time_frame>Approximately 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of BMS-936559</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of BMS-936559</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of BMS-936559</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-936559</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance (CLT) of BMS-936559</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) of BMS-936559</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal serum half-life (T-HALF) of BMS-936559</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receptor occupancy based on PD-L1 receptor occupancy levels</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune system function based on baseline and post-dosing assessments of mHLA-DR expression on monocytes at planned sampling timepoints</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune system function based on absolute lymphocyte counts at planned sampling timepoints</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune system function based on lipopolysaccharide (LPS)-induced whole blood TNFalpha production levels at planned sampling timepoints</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ dysfunction measured by organ support-free days (OSFDs)</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>OSFD is defined as the last period of organ support-free duration during the index hospitalization stay prior to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ dysfunction measured by proportion of OSFDs during index hospitalization</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>OSFD is defined as the last period of organ support-free duration during the index hospitalization stay prior to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation, vasopressor use, and/or dialysis use separately during the index hospitalization</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary infections (as adjudicated by a clinical committee) up to 90 days post administration of BMS-936559</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at 28 days, 90 days, and 1 year after study drug administration</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>All-cause mortality at 28 days, 90 days, and 1 year post administration of BMS-936559.
Time to death will also be used to assess the treatment effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity measured by number of subjects having detectable anti-drug antibodies (ADA) at baseline and following administration of BMS-936559.</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity measured by percentage of subjects having detectable anti-drug antibodies (ADA) at baseline and following administration of BMS-936559.</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>BMS-936559</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-936559 Intravenous infusion on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-936559</intervention_name>
    <arm_group_label>BMS-936559</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Severe sepsis or septic shock for at least 24 hours

          -  Documented or suspected infection

          -  Sepsis-induced immunosuppression

          -  Men and women â‰¥ 18 years old

        Exclusion Criteria:

          -  Autoimmune disease

          -  Organ transplant or bone marrow transplant

          -  Cancer treated in the past 6 months

          -  Hepatitis B virus (HBV) Infection

          -  Human Immunodeficiency Virus (HIV) infection and not on therapy prior to this episode
             of sepsis

          -  Hepatitis C virus (HCV) infection and still has virus (not cured)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uc Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osf Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Division of Acute Care Surgery</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School Of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent'S Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261-2500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

